Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GSK in computing pact with Exscientia

by Lisa M. Jarvis
July 10, 2017 | A version of this story appeared in Volume 95, Issue 28

GlaxoSmithKline has partnered with Exscientia to use artificial intelligence to develop small molecules against up to 10 drug targets. Exscientia seeks to use AI to design molecules with a desired balance of potency, selectivity, and pharmacokinetics. GSK will provide the firm with research funding and up to $42 million in milestone payments as molecules reach preclinical studies. In May, Exscientia joined with Sanofi to develop bispecific small molecules against metabolic diseases targets.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.